Quest Laboratories (NSE:QUESTLAB) Additional Paid-In Capital: ₹0 Mil(As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:QUESTLAB Quest Laboratories Ltd NSE:QUESTLAB
44 GF Score
Price ₹95.00
! 5 Warning Signs
View Full Analysis

What is Quest Laboratories Additional Paid-In Capital?

Quest Laboratories NSE:QUESTLAB +5.56% 44 Additional Paid-In Capital is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:QUESTLAB with a GF Score™ of 44/100. The stock has 5 warning signs investors should review.


Quest Laboratories's quarterly additional paid-in capital declined from Mar. 2025 (₹374 Mil) to Sep. 2025 (₹0 Mil) but then stayed the same from Sep. 2025 (₹0 Mil) to Mar. 2026 (₹0 Mil).

Quest Laboratories's annual additional paid-in capital increased from Mar. 2024 (₹23 Mil) to Mar. 2025 (₹374 Mil) but then declined from Mar. 2025 (₹374 Mil) to Mar. 2026 (₹0 Mil).

Quest Laboratories Additional Paid-In Capital Related Terms

Quest Laboratories Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Quest Laboratories's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quest Laboratories Additional Paid-In Capital Chart

Quest Laboratories Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Additional Paid-In Capital
Get a 7-Day Free Trial 15.98 15.98 23.00 374.20 0.00

Quest Laboratories Semi-Annual Data
Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only 23.00 0.00 374.20 0.00 0.00
NSE:QUESTLAB
44GF Score
Quest Laboratories Ltd NSE:QUESTLAB
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Quest Laboratories Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of ₹0 Mil mean?
Quest Laboratories (NSE:QUESTLAB) has a Additional Paid-In Capital of ₹0 Mil as of Mar. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Quest Laboratories and its competitors.
Is Quest Laboratories' Additional Paid-In Capital too high?
Quest Laboratories' current Additional Paid-In Capital is ₹0 Mil. Overall, Quest Laboratories has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Quest Laboratories' Additional Paid-In Capital compare to LLY and JNJ?
Quest Laboratories' Additional Paid-In Capital of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Drug Manufacturers company?
A good Additional Paid-In Capital depends on the Drug Manufacturers industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Quest Laboratories and its competitors. Quest Laboratories's current Additional Paid-In Capital is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Laboratories stock overvalued right now?
Quest Laboratories (NSE:QUESTLAB) has a current Additional Paid-In Capital of ₹0 Mil. The current Additional Paid-In Capital is ₹0 Mil. Quest Laboratories' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Quest Laboratories (NSE:QUESTLAB), the current Additional Paid-In Capital is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Quest Laboratories Business Description

Address Sector III, Plot No. 45, Pithampur Industrial Area, Opposite Kissan Pipe Unit 4, District Dhar, Pithampur, Dhar, MP, IND, 454775
Quest Laboratories Ltd is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces various products, comprising ethical drugs, generic drugs, and over-the-counter drugs, and is also available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids, among others. The company operates in a single segment of Drugs and Chemicals.
44GF Score

Get the complete analysis for NSE:QUESTLAB

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹95.00
Price